Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines. (Q39315907)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788366 AND SRC:MED&resulttype=core&format=json

7 February 2020

title

Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788366 AND SRC:MED&resulttype=core&format=json

7 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788366 AND SRC:MED&resulttype=core&format=json

7 February 2020

Regina Arantes-Rodrigues

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788366 AND SRC:MED&resulttype=core&format=json

7 February 2020

Palmeira C

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788366 AND SRC:MED&resulttype=core&format=json

7 February 2020

Isabel Gaivao

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788366 AND SRC:MED&resulttype=core&format=json

7 February 2020

Maria Luís Cardoso

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788366 AND SRC:MED&resulttype=core&format=json

7 February 2020

Aura Colaço

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788366 AND SRC:MED&resulttype=core&format=json

7 February 2020

Paula A. Oliveira

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788366 AND SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Lúcio Santos

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788366 AND SRC:MED&resulttype=core&format=json

7 February 2020

publication date

1 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788366 AND SRC:MED&resulttype=core&format=json

Journal of Toxicology and Environmental Health Part A

7 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788366 AND SRC:MED&resulttype=core&format=json

7 February 2020

volume

75

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788366 AND SRC:MED&resulttype=core&format=json

7 February 2020

issue

13-15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788366 AND SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

788-799

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788366 AND SRC:MED&resulttype=core&format=json

Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV.

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

mTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Predictors of competing mortality in advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Therapeutic targets: MTOR and related pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Rapamycins: mechanism of action and cellular resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Bladder Cancer Determination Via Two Urinary Metabolites: A Biomarker Pattern Approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

The Relationship between Treatment Time of Gemcitabine and Development of Hematologic Toxicity in Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Selective cytotoxicity of gemcitabine in bladder cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

-(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Cellular pharmacology of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

The evolution of cancer research and drug discovery at Lilly Research Laboratories

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Effect of sirolimus on urinary bladder cancer T24 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

European Guidelines for the Diagnosis and Management of Upper Urinary Tract Urothelial Cell Carcinomas: 2011 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Sirolimus: its discovery, biological properties, and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Mammalian TOR signaling to the AGC kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Is gemcitabine cost effective in cancer treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Everolimus and mycophenolate mofetil sensitize human pancreatic cancer cells to gemcitabine in vitro: a novel adjunct to standard chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

In vivo and in vitro effects of RAD001 on bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/15287394.2012.690325

10.1080/15287394.2012.690325

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22788366 AND SRC:MED&resulttype=core&format=json

7 February 2020

1 reference